EDT talks about new OSD contracting biz

By Gareth Macdonald and Claire Videau

- Last updated on GMT

US-based Elan Drug Technologies (EDT) says new oral solid dose (OSD) contract manufacturing offering will add value to business.

in-Pharmatechnologist spoke with James Botkin, EDT’s SVP of operations, who explained that the new offering, launched last month​, is based on the manufacturing capacity and capabilities the firm has developed over the last forty years.

Botkin also said that the competitiveness of the new unit, which will focus on the production and development of oral solid dose drugs, is reliant on operating efficiencies established by its core drug delivery business.

He also suggested that, if successful, the OSD service will make EDT a more valuable proposition, which may make it more attractive to potential buyers if parent firm Elan restarts​ efforts to split the unit from its BioNeurology business.

Related news

Show more

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...